225 FRANKLIN STREET, BOSTON, MA
Palvella Therapeutics Expands QTORIN™ Development for Rare Lymphatic Disease
1 First - in - disease therapies for patients with rare genetic skin diseases
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Reports Full Year 2024 Financial Results and Provides Corporate Update, Investor Presentation
Investor Presentation
Q2
Q1
FY 2024
Q3
FY 2023 amended
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Prospectus Filed Pursuant to Rule 425
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership